Radiation-induced cavernous hemangiomas (RICH) are a known complication of radiation exposure, especially in young children. The current treatment approaches to these lesions include observation and surgical resection. We report the case of a 4-year-old male with recurrent medulloblastoma who had resolution of an incidental RICH lesion while being treated with bevacizumab for his recurrent brain tumor. There was no evidence of worsening hemorrhage with this therapy and the RICH did not recur upon discontinuation of the chemotherapy regimen. This is the first documented case of a RICH lesion responding to antiangiogenic therapy, suggesting the possible use of this class of agents in the treatment of symptomatic patients who are not considered appropriate candidates for surgical resection. Although the risk of bleeding must be taken into consideration, antiangiogenic therapies have the potential to be a novel treatment modality for symptomatic RICH lesions.

Keywords:
Bevacizumab, Hemangioma, cavernous, Radiation-induced malformation
1.
Armstrong GT: Long-term survivors of childhood central nervous system malignancies: the experience of the Childhood Cancer Survivor Study. Eur J Paediatr Neurol 2010;14:298–303.
2.
Nimjee SM, Powers CJ, Bulsara KR: Review of the literature on de novo formation of cavernous malformations of the central nervous system after radiation therapy. Neurosurg Focus 2006;21:e4.
3.
Strenger V, Sovinz P, Lackner H, et al: Intracerebral cavernous hemangioma after cranial irradiation in childhood: incidence and risk factors. Strahlenther Onkol 2008;184:276–280.
4.
Heckl S, Aschoff A, Kunze S. Radiation-induced cavernous hemangiomas of the brain: a late effect predominantly in children. Cancer 2002;94:3285–3291.
5.
Brunon J, Nuti C: Natural history of cavernomas of the central nervous system (in German). Neurochirurgie 2007;53:122–130.
6.
Keezer MR, Del Maestro R: Radiation-induced cavernous hemangiomas: case report and literature review. Can J Neurol Sci 2009;36:303–310.
7.
Rigamonti D, Drayer BP, Johnson PC, et al: The MRI appearance of cavernous malformations (angiomas). J Neurosurg 1987;67:518–524.
8.
Jenab-Wolcott J, Giantonio BJ: Bevacizumab: Current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009;9:507–517.
9.
Summers J, Cohen MH, Keegan P, et al: FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010;15:104–111.
10.
Cohen MH, Shen YL, Keegan P, et al: FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14:1131–1138.
11.
Butturini AM, Jacob M, Aguajo J, et al: High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome. Cancer 2009;115:2956–2963.
12.
Larson JJ, Ball WS, Bove KE, et al: Formation of intracerebral cavernous malformations after radiation treatment for central nervous system neoplasia in children. J Neurosurg 1998;88:51–56.
13.
Jung KH, Chu K, Jeong SW, et al: Cerebral cavernous malformations with dynamic and progressive course: correlation study with vascular endothelial growth factor. Arch Neurol 2003;60:1613–1618.
14.
Kilic T, Pamir MN, Kullu S, et al: Expression of structural proteins and angiogenic factors in cerebrovascular anomalies. Neurosurgery 2000;46:1179–1191, discussion 1191–1192.
15.
Maeder P, Gudinchet F, Meuli R, et al: Development of a cavernous malformation of the brain. AJNR Am J Neuroradiol 1998;19:1141–1143.
16.
Hilder TL, Malone MH, Bencharit S, et al: Proteomic identification of the cerebral cavernous malformation signaling complex. J Proteome Res 2007;6:4343–4355.
17.
Marchuk DA, Srinivasan S, Squire TL, et al: Vascular morphogenesis: tales of two syndromes. Hum Mol Genet 2003;12:R97–R112.
18.
Tirakotai W, Fremann S, Soerensen N, et al: Biological activity of paediatric cerebral cavernomas: an immunohistochemical study of 28 patients. Childs Nerv Syst 2006;22:685–691.
19.
Mahajan D, Miller C, Hirose K, et al: Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. J Hepatol 2008;49:867–870.
20.
Ach T, Thiemeyer D, Hoeh AE, et al: Intravitreal bevacizumab for retinal capillary haemangioma: long-term results. Acta Ophthalmol 2010;88:137–138.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.